Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs BEAM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRNA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

MRNA Overall Winner 6-Pillar Tally: MRNA 5 – 1 BEAM Matrix Metrics: MRNA 7 – 3 BEAM

As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Beam Therapeutics Inc. (BEAM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas BEAM carries 60.3/100 (BUY) at $20.90 (N/M Forward P/E, -267.7% operating margin).

  • Composite vs. Pillar Nuance: While BEAM currently prints a higher short-term Unified Composite Score (60.3/100 BUY vs. MRNA 40.3/100 SELL), MRNA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-80.8% vs. -267.7% operating margin) and revenue trajectory (+29.2% vs. -96.8% YoY).
  • Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs BEAM
MRNA NASDAQ Head-to-Head Winner
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
BEAM NASDAQ
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$20.90
-0.19% 1D
Market Cap $2.2B
TTM Revenue $147M
Forward P/E N/M
Beta / 30D Vol 2.09β · 86% Vol
Unified Composite Score
60.3 / 100 BUY
Tech 70.0 Fund 66.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.3%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $24.75 · SMA50: $24.63

6-Pillar Scorecard Institutional Category Breakdown (MRNA 5 – 1 BEAM)

Columns: Metric · MRNA · BEAM
1. Valuation Multiples MRNA
Forward P/E 23.0x N/M
Trailing P/E 23.0x N/M
PEG Ratio N/M N/M
EV / Revenue 33.1x 15.3x
2. Growth & Scale MRNA
Revenue Growth (YoY) +29.2% -96.8%
Earnings Growth (YoY) -85.1% +0.0%
TTM Revenue (USD) $2.52B $147M
Market Cap $80.7B $2.2B
3. Profitability & Quality MRNA
Gross Margin -42.0% N/A
Operating Margin -80.8% -267.7%
Net Profit Margin -110.5% -73.9%
Return on Equity (ROE) -34.5% -11.3%
4. Balance Sheet & Cash Flow BEAM
Cash Generation (TTM) -$2.04B -$398M
Cash Flow Margin -81.0% N/A
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $31M Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 89.6% (52nd %ile) 87.4% (34th %ile)
Put/Call OI Skew 1.05x (Balanced) 2.31x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (7) vs BEAM (3)
Institutional Metric MRNA BEAM Criterion Row Edge
Market Capitalization
Scale
$80.7B $2.2B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x N/M Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+29.2% -96.8% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% -267.7% Higher Margin MRNA
Net Profit Margin
Profitability
-110.5% -73.9% Higher Margin BEAM
Return on Equity (ROE)
Capital Efficiency
-34.5% -11.3% Higher ROE BEAM
52-Week Range Position
Momentum
67% ($22–$281) 4% ($20–$38) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 2.09β · 86% Vol Lower Realized Risk MRNA
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 60.3 / 100 (BUY) Higher Composite BEAM
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $147M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev N/M PEG · 15.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) -$398M ($31M Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRNA +11.13 pp
MRNA: -3.77% · BEAM: -14.9%
3M Horizon MRNA +66.63 pp
MRNA: +40.4% · BEAM: -26.23%
6M Horizon MRNA +342.99 pp
MRNA: +315.96% · BEAM: -27.03%
1Y Horizon MRNA +706.83 pp
MRNA: +706.45% · BEAM: -0.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRNA Revenue BEAM Revenue MRNA Op. Margin BEAM Op. Margin Margin Leader
FY2018 $140M N/A -306.0% N/A MRNA
FY2019 $60M $0M -906.8% -417522.2% MRNA
FY2020 $800M $0M -95.0% -553166.7% MRNA
FY2021 $18.5B $50M 72.0% -757.0% MRNA
FY2022 $19.3B $60M 48.9% -555.6% MRNA
FY2023 $6.85B $380M -61.9% -46.7% BEAM
FY2024 $3.24B $60M -121.9% -654.3% MRNA
FY2025 $1.94B $140M -158.1% -274.6% MRNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BEAM BREAKDOWN
107d in phase · OBV DISTRIBUTION
Current IV 87.4%
IV Percentile 34th %ile
Put/Call OI Skew 2.31x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA vs. BEAM: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of MRNA ($21,527) vs. BEAM ($2,094) against risk-defined 5-day vertical and put-wall option structures.

MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
BEAM Spot $20.94 · IV 74.7%
BEAM Options Simulator →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $20 / $18 Bull Put Spread

Sell 2x $20P · Buy 2x $18P · 28d

Net Entry $102 Credit
Max Credit / Yield +$102 (+34.2% RoM)
Max Risk / Buffer -6.9% Cushion ($298 Mgn)
5d Edge & Liquidity 63% PoP · Liq C
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $23 / $20 Bear Put Spread

Buy 1x $23P · Sell 1x $20P · 28d

Net Entry $179 Debit
T+5d @ -5% Drop +$28 (+16%)
Max Risk / Buffer $179 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
BEAM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -267.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs BEAM Key Questions & Quantitative Answers

As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Beam Therapeutics Inc. (BEAM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas BEAM carries 60.3/100 (BUY) at $20.90 (N/M Forward P/E, -267.7% operating margin). Composite vs. Pillar Nuance: While BEAM currently prints a higher short-term Unified Composite Score (60.3/100 BUY vs. MRNA 40.3/100 SELL), MRNA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-80.8% vs. -267.7% operating margin) and revenue trajectory (+29.2% vs. -96.8% YoY). Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with BEAM at -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while BEAM shifted +180.0%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BEAM.

MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus BEAM (-11.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, BEAM carries 87.4% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 2.31x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.09β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.